| BPC-157 Checked 2026-06-27 Related briefing | injury recovery, gut repair, inflammation | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:High riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| TB-500 Checked 2026-06-27 Related briefing | recovery, mobility, soft-tissue repair | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:High riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| KPV Checked 2026-06-27 Related briefing | recovery, metabolic, immune or anti-aging claims | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:Moderate riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| MOTs-C Checked 2026-06-27 Related briefing | recovery, metabolic, immune or anti-aging claims | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:Moderate riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| DSIP / Emideltide Checked 2026-06-27 Related briefing | recovery, metabolic, immune or anti-aging claims | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:Moderate riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| Semax Checked 2026-06-27 Related briefing | recovery, metabolic, immune or anti-aging claims | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:Moderate riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| Epitalon Checked 2026-06-27 Related briefing | recovery, metabolic, immune or anti-aging claims | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:Moderate riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| GHK-Cu Checked 2026-06-27 Related briefing | recovery, metabolic, immune or anti-aging claims | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:Moderate riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| CJC-1295 Checked 2026-06-27 Related briefing | recovery, metabolic, immune or anti-aging claims | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:Moderate riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| Ipamorelin Checked 2026-06-27 Related briefing | recovery, metabolic, immune or anti-aging claims | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:Moderate riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| Sermorelin Checked 2026-06-27 Related briefing | growth-hormone axis support, aging clinics | Verify product-specific approval and compounding status | Evidence:Regulatory watchRisk:Moderate riskStatus:Status unclear Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| AOD-9604 Checked 2026-06-27 Related briefing | recovery, metabolic, immune or anti-aging claims | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:Moderate riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |
| Thymosin alpha-1 Checked 2026-06-27 Related briefing | recovery, metabolic, immune or anti-aging claims | Not an FDA-approved longevity product; verify compounding status | Evidence:Regulatory watchRisk:Moderate riskStatus:Not FDA-approved Evidence varies by compound and claim; most longevity uses need stronger human outcome evidence before publication-grade confidence. Regulatory uncertainty, product identity, contamination, adverse effects, inappropriate medical use and overconfident marketing. | FDA compounding resources |